Claims for Patent: 10,646,431

Summary for Patent: 10,646,431

Title:	PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Abstract:	Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/soluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
Inventor(s):	Marathi Upendra K., Childress Susann Edler, Gammill Shaun L., Strozier Robert W.
Assignee:	PLx Opco Inc.
Application Number:	US16183616
Patent Claims:	1. A pharmaceutical composition formulated for oral administration comprising a suspension of solid particles of a biologically active agent in a non-aqueous liquid carrier , wherein the non-aqueous liquid carrier is an oil , and wherein the carrier comprises:(a) at least about 10 wt. % of free monocarboxylic acid having at least 8 carbons, wherein the monocarboxylic acid is liquid at room temperature; and(b) less than about 10 wt. % zwitterionic phospholipid;wherein the pharmaceutical composition releases a lesser amount of active agent at a pH of <3 than at pH >3, andwherein the pharmaceutical composition is formulated in the absence of a solvent.2. The pharmaceutical composition of claim 1 , wherein the composition consists essentially of a suspension of solid biologically active agent in the non-aqueous liquid carrier.3. The pharmaceutical composition of claim 1 , wherein the carrier further comprises a neutral lipid.4. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier comprises at least about 14 wt. % of free monocarboxylic acid having at least 8 carbons.5. The pharmaceutical composition of claim 1 , wherein the carrier comprises less than about 7.5 wt. % of zwitterionic phospholipid.6. The pharmaceutical composition of claim 1 , wherein:(a) less than about 20% of the biologically active agent is released from the non-aqueous liquid carrier at pH<3; and(b) greater than about 50% of the biologically active agent is released from the non-aqueous liquid carrier at pH >3.7. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier releases a lesser amount of biologically active agent at pH<5 than at pH >5.8. The pharmaceutical composition of claim 1 , wherein the weight ratio of the active agent to the non-aqueous liquid carrier is between about 50: about 1 and about 1: about 10.9. The pharmaceutical composition of claim 1 , wherein the carrier comprises one monocarboxylic acid or a plurality of monocarboxylic acids.10. The pharmaceutical composition of claim 1 , wherein the carrier comprises a mixture of different monocarboxylic acids having at least 8 carbons.11. The pharmaceutical composition of claim 1 , wherein the carrier comprises up to about 40 wt. % monocarboxylic acids.12. The pharmaceutical composition of claim 1 , wherein the biologically active agent comprises at least one agent selected from the group consisting of an acid-labile pharmaceutical agent claim 1 , an anti-depressant claim 1 , an anti-diabetic agent claim 1 , an anti-epileptic agent claim 1 , an anti-fungal agent claim 1 , an anti-malarial agent claim 1 , an anti-muscarinic agent claim 1 , an anti-neoplastic agent claim 1 , an immunosuppressant claim 1 , an anti-protozoal agent claim 1 , an anti-tussive claim 1 , a neuroleptics claim 1 , a beta-blocker claim 1 , a cardiac inotropic agent claim 1 , a corticosteroid claim 1 , an anti-parkinsonian agent claim 1 , a gastrointestinal agent claim 1 , histamine claim 1 , a histamine receptor antagonist claim 1 , a keratolytic claim 1 , a lipid regulating agent claim 1 , a muscle relaxant claim 1 , a nitrate claim 1 , an anti-anginal agent claim 1 , a nutritional agent claim 1 , an opioid analgesic claim 1 , a sex hormone claim 1 , a stimulant claim 1 , a nutraceutical claim 1 , a peptide claim 1 , a protein claim 1 , a therapeutic protein claim 1 , a nucleoside claim 1 , a nucleotide claim 1 , DNA claim 1 , RNA claim 1 , a glycosaminoglycan claim 1 , an acid-labile drug claim 1 , (+)-N{3-[3-(4-fluorophenoxy)phenyl]-2-cyclopenten-1-yl}-N-hydroxyurea claim 1 , amylase claim 1 , aureomycin claim 1 , bacitracin claim 1 , beta carotene claim 1 , cephalosporins claim 1 , chloromycetin claim 1 , cimetidine claim 1 , cisapride claim 1 , cladribine claim 1 , clorazepate claim 1 , deramciclane claim 1 , didanosine claim 1 , digitalis glycosides claim 1 , dihydrostreptomycin claim 1 , erythromycin claim 1 , etoposide claim 1 , famotidine claim 1 , a hormone claim 1 , estrogen claim 1 , insulin claim 1 , adrenalin claim 1 , heparin claim 1 , lipase claim 1 , milameline claim 1 , novobiocin claim 1 , pancreatin claim 1 , penicillin salts claim 1 , polymyxin claim 1 , pravastatin claim 1 , progabide claim 1 , protease claim 1 , quinapril claim 1 , quinoxaline-2-carboxylic acid claim 1 , [4-(R)carbamoyl-1-(S-3-fluorobenzyl-2-(S) claim 1 ,7-dihydroxy-7-methyloctyl]amide claim 1 , quinoxaline-2-carboxylic acid[1-benzyl-4-(4 claim 1 ,4-difluoro-1-hydroxy-cyclohexyl)-2-hydroxy-4-hydroxycarbamoyl-butyl]-amide ranitidine claim 1 , streptomycin claim 1 , subtilin claim 1 , sulphanilamide claim 1 , a proton pump inhibitors claim 1 , esomeprazole claim 1 , lansoprazole claim 1 , minoprazole claim 1 , omeprazole claim 1 , pantoprazole and rabeprazole.13. The pharmaceutical composition of claim 1 , wherein the biologically active agent is an acid-labile drug.14. The pharmaceutical composition of claim 13 , wherein the acid-labile drug is selected from the group consisting of heparin claim 13 , insulin claim 13 , erythropoietin claim 13 , pancreatin claim 13 , lansoprazole claim 13 , omeprazole claim 13 , pantoprazole claim 13 , rabeprazole claim 13 , penicillin salts claim 13 , benzathine penicillin claim 13 , polymyxin claim 13 , sulphanilamide claim 13 , and erythromycin.15. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier further comprises at least one component selected from the group consisting of an adjuvant claim 1 , a mixture of adjuvants claim 1 , an antioxidant claim 1 , a mixture of antioxidants claim 1 , a viscomodulator claim 1 , a mixture of viscomodulators claim 1 , and a permeability-improving agent.16. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier is substantially free of fatty acid salt.17. A pharmaceutical composition formulated for oral administration comprising a suspension of solid particles of a weak-acid non-steroidal anti-inflammatory drug (NSAID) in a non-aqueous liquid carrier claim 1 , wherein the non-aqueous liquid carrier is an oil claim 1 , and wherein the carrier comprises:(a) at least about 10 wt. % of free monocarboxylic acid having at least 8 carbons, wherein the monocarboxylic acid is liquid at room temperature; and(b) less than about 10 wt. % zwitterionic phospholipid;wherein the pharmaceutical composition releases a lesser amount of active agent at a pH of <3 than at pH >3, andwherein the pharmaceutical composition is formulated in the absence of a solvent.18. The pharmaceutical composition of claim 17 , wherein the NSAID is selected from the group consisting of ibuprofen claim 17 , piroxicam claim 17 , salicylate claim 17 , aspirin claim 17 , naproxen claim 17 , indomethacin claim 17 , diclofenac claim 17 , mefenamic acid claim 17 , COX2 inhibitors claim 17 , and any mixture thereof.19. The pharmaceutical composition of claim 18 , wherein the NSAID is selected from the group consisting of aspirin claim 18 , naproxen claim 18 , indomethacin and mefenamic acid.20. The pharmaceutical composition of claim 17 , wherein:(a) the NSAID is released at pH values of less than pH 2 at a rate of less than about 20% in thirty minutes, and(b) the NSAID is released at pH values above about pH 3, at a rate of greater than about 80% in thirty minutes.21. The pharmaceutical composition of claim 1 , wherein the amount of zwitterionic phospholipids is selected from the group consisting of about 0.5 wt. % claim 1 , about 1 wt. % claim 1 , about 2 wt. % claim 1 , about 2.5 wt. % claim 1 , about 5 wt. % claim 1 , and about 7.5 wt. %.